BioInvent International AB (fra:BIX0) Share Price

Company Profile

Business description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Contact
Ideongatan 1
LundSE-223 70
SWE
T: +46 462868550
E: [email protected]
https://www.bioinvent.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
122

Recommended

With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.

Simonelle Mody | 24 September 2025

Big AI dreams as firms announce a strategic partnership.

Brian Colello, CPA | 24 September 2025

We see gross margin expansion on efficiencies and limited tariff impact

Shani Jayamanne | 24 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,063.40	33.90	0.38%
CAC 40	7,785.56	41.89	-0.54%
DAX 40	23,522.67	144.14	-0.61%
Dow JONES (US)	46,121.28	171.50	-0.37%
FTSE 100	9,226.72	23.71	-0.26%
HKSE	26,484.68	33.97	-0.13%
NASDAQ	22,497.86	75.62	-0.33%
Nikkei 225	45,754.93	124.62	0.27%
NZX 50 Index	13,153.79	27.52	-0.21%
S&P 500	6,637.97	18.95	-0.28%
S&P/ASX 200	8,773.00	35.10	0.40%
SSE Composite Index	3,853.30	0.34	-0.01%